Eli Lilly reported that combining Zepbound (tirzepatide) with the immunology drug Taltz improved symptoms in obese patients with psoriatic arthritis compared to Taltz alone. The findings suggest the GLP-1 drug may have benefits beyond weight loss, potentially aiding those with autoimmune joint pain. Despite the positive data, the drug's prescribing patterns are likely to remain driven by its primary weight loss indications.